Modulation of the Channel Activity of the epsilon 2/zeta 1-Subtype N-Methyl D-Aspartate Receptor by PSD-95*

Yasue YamadaDagger , Yasuyo ChochiDagger , Kougo Takamiya§, Kenji Sobue§, and Makoto InuiDagger

From the Dagger  Department of Pharmacology, Yamaguchi University School of Medicine, 1144 Kogushi, Ube, Yamaguchi 755-8505, Japan and the § Department of Neurochemistry and Neuropharmacology, Osaka University Medical School, Yamadaoka 2-2, Suita, Osaka 565-0871, Japan

    ABSTRACT
Top
Abstract
Introduction
References

A channel-associated protein PSD-95 has been shown to induce clustering of N-methyl D-aspartate (NMDA) receptors, interacting with the COOH terminus of the epsilon  subunit of the receptors. The effects of PSD-95 on the channel activity of the epsilon 2/zeta 1 heteromeric NMDA receptor were examined by injection of PSD-95 cRNA into Xenopus oocytes expressing the NMDA receptors. Expression of PSD-95 decreased the sensitivity of the NMDA receptor channels to L-glutamate. Mutational studies showed that the interaction between the COOH terminus of the epsilon 2 subunit of the NMDA receptor and the second PSD-95/Dlg/Z0-1 domain of PSD-95 is critical for the decrease in glutamate sensitivity. It is known that protein kinase C markedly potentiates the channel activity of the NMDA receptor expressed in oocytes. PSD-95 inhibited the protein kinase C-mediated potentiation of the channels. Thus, we demonstrated that PSD-95 functionally modulates the channel activity of the epsilon 2/zeta 1 NMDA receptor. PSD-95 makes signal transmission more efficient by clustering the channels at postsynaptic sites. In addition to this, our results suggest that PSD-95 plays a protective role against neuronal excitotoxicity by decreasing the glutamate sensitivity of the channels and by inhibiting the protein kinase C-mediated potentiation of the channels.

    INTRODUCTION
Top
Abstract
Introduction
References

The NMDA1 receptor is a subclass of ionotropic glutamate receptors in the mammalian brain. The NMDA receptors exhibit several channel properties distinct from other non-NMDA glutamate receptors, including a high Ca2+/Na+ permeability ratio, a voltage-dependent Mg2+ block, and a requirement for glycine as co-agonist (1-4). The receptors are modulated by phosphorylation catalyzed by protein kinase C (5, 6) and by tyrosine kinases (7, 8). In brain, functional NMDA receptors are thought to exist as heteromultimers of the zeta 1 subunit (NR1) with epsilon  subunits (NR2 subunits). Different combinations of these subunits exhibit distinct channel properties and characteristic regional and developmental expression in vivo (9-11). Disruption of the zeta 1 gene is lethal in mice (12), whereas that of the epsilon 1 and epsilon 2 genes results in reduced channel activity and reduced LTP in the hippocampus (13, 14). A number of evidences indicate that the activation of NMDA receptors is essential for induction of LTP, which underlies the formation and storage of some forms of memories (15).

NR2 subunits (epsilon  subunits) have been shown to interact specifically with PSD-95 (postsynaptic density-95) (16-19). The latter protein is a member of the channel-associated proteins (PSD-95 family), including SAP97 (synaptic associated protein 97)/hdlg (20, 21), chapsin-110/PSD-93 (22, 23), and SAP102 (24). This family of proteins is characterized by the presence of three domains with a length of ~90 amino acids (PDZ domain) in the NH2-terminal region, followed by SH3 and guanylate kinase-like domains. PSD-95 was shown to interact with the COOH-terminal E(T/S)XV sequence motif of NMDA receptor epsilon  subunits (18, 19) and of K+ channels through the NH2-terminal PDZ domains (25, 26). The interaction of these proteins induces the clustering of the channel proteins (23, 25, 27). Thus, PSD-95 plays an important role in the molecular organization of NMDA receptors at postsynaptic sites. Although PSD-95 was shown to enhance the channel activity of the inward rectifier K+ channel Kir4.1 (27), it is not known whether PSD-95 directly affects the channel activities of the NMDA receptors.

In this study, we examined the effects of PSD-95 on epsilon 2/zeta 1 heteromeric NMDA receptor channels expressed in Xenopus oocytes. We found that PSD-95 modulates the channel activity of the NMDA receptor. PSD-95 decreases the sensitivity of the channels to L-glutamate and inhibits the protein kinase C-mediated potentiation of the channels.

    EXPERIMENTAL PROCEDURES

Preparation of cRNA and Oocytes-- Plasmids pBKSAzeta 1, pBKSAepsilon 1, and pBKSAepsilon 2 containing cDNAs encoding mouse brain zeta 1, epsilon 1, and epsilon 2 subunits of the NMDA receptor, respectively, were kindly provided by Dr. Masayoshi Mishina (6, 28). Complementary RNAs of NMDA receptors were synthesized in vitro with T3 RNA polymerase using NotI-cleaved plasmids as templates. The coding region of PSD-95 was amplified by polymerase chain reaction from a rat brain cDNA library. The resulting product was subcloned into pSP64 poly(A) vector (Promega, Madison, WI). The construction was confirmed by dideoxynucleotide sequencing. The PSD-95 cRNA was synthesized in vitro with SP6 RNA polymerase using EcoRI-cleaved plasmid. Deletion and site-specific mutants of the NMDA receptor epsilon 2 subunit and PSD-95 were constructed by polymerase chain reaction strategy using Pfu polymerase (Stratagene, La Jolla, CA) (see Fig. 7A). The wild-type epsilon 2 subunit and PSD-95 were used as polymerase chain reaction templates for mutation, except the C(3,5)SDelta PDZ(1+2) construct, for which the Delta PDZ(1+2) construct was used as a template. Mutations were verified by dideoxynucleotide sequencing.

Stage V and VI oocytes were obtained from anesthetized Xenopus laevis and incubated for 2 h at room temperature with 2 mg/ml collagenase in Barth's medium (88 mM NaCl, 1 mM KCl, 0.33 mM Ca(NO3)2, 0.41 mM CaCl2, 0.82 mM MgSO4, 2.4 mM NaHCO3, and 7.7 mM Tris-HCl, pH 7.2) containing 18 units/ml penicillin and 18 µg/ml streptomycin without Ca2+. The follicular cell layer was then removed with forceps. The oocytes were injected with epsilon 2 and zeta 1 cRNAs at a molar ratio of 1:2. The total amounts of cRNA injected were 5 ng/oocyte. For co-expression of PSD-95, the synthesized PSD-95 cRNA (1-25 ng) was injected 24 h after injection of the NMDA receptor cRNAs. Before recording, oocytes were incubated at 19 °C for 18-26 h in Barth's medium.

Electrophysiological Recordings-- Currents were recorded with two-electrode voltage-clamp techniques using a CA-1a high performance oocyte clamp (Dagan Corp., Minneapolis, MN). Electrodes were filled with 3 M KCl and had resistances of 1-5 megaohms. Oocytes were perfused by a constant stream of Ba2+ Ringer solution (115 mM NaCl, 2.5 mM KCl, 1.8 mM BaCl2, and 10 mM HEPES, pH 7.2) at 23-25 °C. The oocyte membrane was voltage-clamped at -70 mV. In the standard assay, currents were evoked by bath perfusion of Ba2+ Ringer solution containing 100 µM L-glutamate and 10 µM glycine for 20 s, followed by a washout with standard Ba2+ Ringer solution. Current signals were digitized for analyses; statistical significance was determined using Student's t test.

Immunoblotting-- Polyclonal antibodies against the NMDA receptor epsilon 2 and zeta 1 subunits were obtained from Calbiochem and Santa Cruz Biotechnology (Santa Cruz, CA), respectively. Monoclonal antibody against the central region (amino acids 353-504) of rat PSD-95 was obtained from Transduction Laboratories (Lexington, KY). Polyclonal antibodies against PSD-95 were raised in rabbits using a glutathione S-transferase fusion protein with the NH2-terminal region (amino acids 4-404) of rat PSD-95 as immunogen and were affinity-purified. For immunoblotting of PSD-95, oocytes were solubilized with Laemmli gel sample buffer containing 2% SDS (50 µl/oocyte) (29). For immunoblotting of the NMDA receptor, the total membrane fraction was prepared from oocytes. After measurement of current responses, oocytes were homogenized with 100 mM NaCl, 5 mM EDTA, and 20 mM Tris-HCl, pH 7.5, and then centrifuged at 1000 × g for 10 min. The supernatant was centrifuged at 200,000 × g for 30 min. The obtained pellet (total membrane fraction) was solubilized with Laemmli gel sample buffer. The samples were separated by SDS-polyacrylamide gel electrophoresis on 5 or 7.5% gels and transferred to nitrocellulose sheets. After blocking with 5% skim milk and 0.05% Tween 20 in Tris-HCl-buffered saline, the sheets were incubated with primary antibodies in the blocking solution. Labeled bands were visualized using enhanced chemiluminescence (Pierce). The bands were analyzed by densitometric scanning using Densitograph AE-6900M (Atto Corp., Tokyo, Japan). The amounts of the proteins were quantified from the intensity of the bands, which has a linearity to the amounts of the samples applied to the gel.

    RESULTS

Characterization of epsilon 2/zeta 1 Heteromeric NMDA Receptor Channels in Oocytes Co-expressing PSD-95-- To investigate the effects of PSD-95 on the channel activities of the epsilon 2 (NR2B)/zeta 1 (NR1a) heteromeric NMDA receptor, we expressed the NMDA receptor and PSD-95 in Xenopus oocytes by injection of in vitro synthesized cRNAs. When the expression of the proteins was monitored by immunoblotting, the level of the NMDA receptor reached a plateau ~40 h after injection of the cRNAs and was then constant for several days (data not shown). On the other hand, the level of PSD-95 rapidly increased to the maximum within 24 h after injection and then decreased (data not shown). Therefore, in this study, PSD-95 cRNA was injected into oocytes that were already expressing the NMDA receptor, and the effects of PSD-95 on the NMDA receptor channels were examined 18-26 h after injection of PSD-95 cRNA, measuring current responses to 100 µM L-glutamate and 10 µM glycine in Ba2+ Ringer solution under voltage clamp at -70 mV. However, the results obtained with these oocytes were qualitatively the same as those obtained with oocytes in which cRNAs of the NMDA receptor and PSD-95 were co-injected.

To characterize the channels in oocytes co-expressing PSD-95, we first examined the effects of ifenprodil on the channel activity. Ifenprodil is known to selectively block epsilon 2/zeta 1 heteromeric NMDA receptor channels (30). Ifenprodil completely inhibited the channels in oocytes co-expressing the receptor and PSD-95, as in oocytes expressing the receptor alone, whereas it had no effect on other subtypes of NMDA receptor channels such as the epsilon 1/zeta 1 heteromeric receptor (Fig. 1). These results indicate that the current responses in oocytes co-expressing the receptor with PSD-95 are indeed through epsilon 2/zeta 1 NMDA receptor channels. The average of the current responses from 15 oocytes was 1.34 ± 0.56 µA (mean ± S.D., n = 15) in oocytes expressing the NMDA receptor and 2.56 ± 1.00 µA (mean ± S.D., n = 15) in oocytes co-expressing PSD-95. When the expression of the receptor was compared in these oocytes by immunoblotting, the expression level of the receptor was proportional to the current response, and the ratio between epsilon 2 and zeta 1 subunits was not changed by PSD-95 (Fig. 2). These results indicate that PSD-95 does not inhibit the expression or plasma membrane insertion of the receptor. A higher expression level of the receptor in oocytes co-expressing PSD-95 might be due to the stabilization of the receptor by interacting with PSD-95. However, the amplitudes of evoked currents varied from oocyte to oocyte and could not simply be compared between oocytes expressing the receptor and co-expressing PSD-95. In this study, we focused on the qualitative differences in the channel properties between them. When the channel activities were measured at various concentrations of glutamate, the dose-response curve shifted to the right in oocytes co-expressing the receptor and PSD-95 (Fig. 3). The EC50 was increased from 1.39 to 5.76 µM by injection of PSD-95 cRNA. Thus, PSD-95 significantly decreased the sensitivity of the channels to glutamate. On the other hand, PSD-95 did not change other basic properties of the NMDA receptor such as a requirement for glycine as co-agonist, the current-voltage relationship, and a voltage-dependent Mg2+ block of the channels (data not shown).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 1.   Effects of ifenprodil on L-glutamate-induced current responses in Xenopus oocytes expressing NMDA receptors and PSD-95. Current responses were measured in oocytes injected with in vitro synthesized cRNAs of the epsilon 2/zeta 1 NMDA receptor (A), the epsilon 2/zeta 1 NMDA receptor and PSD-95 (B), or the epsilon 1/zeta 1 NMDA receptor (C). In B, 25 ng of PSD-95 cRNA was injected into an oocyte 24 h after injection of NMDA receptor cRNAs. The responses were measured in Mg2+-free Ba2+ Ringer solution at -70-mV membrane potential. Representative tracings are presented. Bars show the duration of application of 100 µM L-glutamate and 10 µM glycine. In the traces on the right, 100 µM L-glutamate and 10 µM glycine were applied in the presence of 10 µM ifenprodil. Inward current is downward.


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 2.   Expression of the epsilon 2/zeta 1 NMDA receptor in Xenopus oocytes. Oocytes were injected with cRNAs of the epsilon 2/zeta 1 NMDA receptor (lanes 1) and epsilon 2/zeta 1 NMDA receptor and PSD-95 (lanes 2). PSD-95 cRNA (25 ng) was injected into oocytes expressing the epsilon 2/zeta 1 NMDA receptor. After measurement of current responses, 15 oocytes were combined, and the total membrane fraction was prepared as described under "Experimental Procedures." The samples were separated by SDS-polyacrylamide gel electrophoresis on a 5% gel. Immunoblotting was performed with antibodies against the epsilon 2 (A) and zeta 1 (B) subunits of the NMDA receptor. The average of the currents evoked by 100 µM L-glutamate and 10 µM glycine was 1.34 ± 0.56 µA (mean ± S.D., n = 15) in oocytes expressing the NMDA receptor and 2.56 ± 1.00 µA (mean ± S.D., n = 15) in oocytes co-expressing PSD-95. The amounts of expressed NMDA receptor were estimated by densitometric scanning of the immunoblot. The ratios of the amounts of expressed epsilon 2 and zeta 1 subunits were 1:1.97 and 1:2.05, respectively, between oocytes expressing the NMDA receptor and co-expressing PSD-95.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 3.   Dose-response curves for L-glutamate in oocytes expressing the epsilon 2/zeta 1 NMDA receptor and PSD-95. Various concentrations of L-glutamate with 10 µM glycine were applied, and the steady-state currents were measured in oocytes injected with epsilon 2/zeta 1 NMDA receptor cRNAs (closed circles) and with epsilon 2/zeta 1 NMDA receptor and PSD-95 cRNAs (open circles). PSD-95 cRNA (25 ng) was injected 24 h after injection of NMDA receptor cRNAs. Each point represents the mean ± S.E. of the current amplitudes obtained from five oocytes. Theoretical curves were drawn according to the equation I = Imax/(1 + (EC50/A)n), where I represents the current response, Imax is the maximum response, A is the concentration of L-glutamate, and n is the Hill coefficient. The EC50 values were 1.39 and 5.76 µM for oocytes expressing the epsilon 2/zeta 1 NMDA receptor and co-expressing PSD-95, respectively, and the Hill coefficient values were 1.29 and 1.07, respectively.

Effects of PSD-95 on the Protein Kinase C-mediated Potentiation of the Channels-- It was reported that the channel activity of the epsilon 2/zeta 1 NMDA receptor in oocytes is markedly potentiated by treatment with TPA, due to activation of protein kinase C (28, 31, 32). Under our assay conditions, the evoked currents were ~4-fold increased by 1 µM TPA in oocytes expressing the NMDA receptor (Figs. 4 and 5). In oocytes co-expressing PSD-95, however, little potentiation of the channel activity (~1.3-fold) was observed with TPA treatment (Figs. 4 and 5). This inhibitory effect of PSD-95 on the potentiation of the channels by TPA was dependent on the amounts of PSD-95 cRNA injected into an oocyte (Fig. 5). To rule out the possibility that PSD-95 directly modulates protein kinase C in oocytes, we examined the effects of PSD-95 on the metabotropic glutamate receptor. The activity of metabotropic glutamate receptors in oocytes can be estimated by the channel activity of Ca2+-activated chloride channels. When expressed in oocytes, metabotropic glutamate receptor-5 showed pronounced desensitization in response to an activation by 1 mM glutamate (data not shown), as reported previously (33). This desensitization has been shown to require protein kinase C-catalyzed phosphorylation of the receptor (33). Indeed, a brief treatment with TPA after activation by glutamate prolonged the desensitization. Co-expression of PSD-95 had no effect on the desensitization upon activation by 1 mM glutamate or on the prolonged desensitization by TPA (data not shown), indicating that expression of PSD-95 does not change the activity of protein kinase C in oocytes.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of TPA on current responses in oocytes expressing the epsilon 2/zeta 1 NMDA receptor and PSD-95. Current responses were measured in oocytes expressing the epsilon 2/zeta 1 NMDA receptor (A) and co-expressing PSD-95 (B) before and after bath application of 1 µM TPA for 10 min. Bars show the duration of application of 100 µM L-glutamate and 10 µM glycine.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 5.   Dose-dependent effects of PSD-95 on the protein kinase C-mediated potentiation of NMDA receptor channels. Various amounts (1-25 ng/oocyte) of PSD-95 cRNA were injected into oocytes expressing the epsilon 2/zeta 1 NMDA receptor. The potentiation of the current response after TPA treatment (at 1 µM for 10 min) was plotted against the amounts of PSD-95 cRNA injected into an oocyte. The data shown are the mean ± S.E. of four oocytes.

Analyses of the Channel Modulation by PSD-95 Using the Deletion Mutant of the NMDA Receptor-- PSD-95 has been shown to interact with the COOH terminus of the NMDA receptor epsilon 2 subunit through the first two PDZ domains (18, 19, 25). To clarify a role of this interaction in the modulation of glutamate sensitivity, the effects of PSD-95 were examined on the mutant NMDA receptor that lacks the COOH-terminal four amino acid residues of the epsilon 2 subunit. The change in the sensitivity to glutamate was monitored by the ratio of current response at 100 µM glutamate to that at 10 µM. In accord with the dose-response curves (Fig. 3), expression of PSD-95 increased the ratio from 1 to ~1.5 in oocytes expressing the wild-type NMDA receptor (Fig. 6). In oocytes expressing the mutant receptors, however, the ratio remained ~1 regardless of PSD-95 expression (Fig. 6). These data indicate that the interaction of the COOH-terminal region of the epsilon 2 subunit with the PDZ domain of PSD-95 is essential for a decrease in sensitivity to glutamate.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of PSD-95 on the glutamate sensitivity of wild-type and mutant NMDA receptor channels. PSD-95 cRNA (25 ng) was injected into oocytes expressing the wild-type epsilon 2/zeta 1 NMDA receptor and into the mutant epsilon 2/zeta 1 NMDA receptor lacking the COOH-terminal four amino acid residues of the epsilon 2 subunit. A ratio of current responses between 100 and 10 µM L-glutamate in the presence of 10 µM glycine is presented. The data shown are the mean ± S.E. of the number of oocytes indicated in parentheses. *, p < 0.01 compared with oocytes expressing the epsilon 2/zeta 1 NMDA receptor without PSD-95.

Analyses of the Channel Modulation by PSD-95 Using Mutant PSD-95-- The modulation of glutamate sensitivity by PSD-95 was further analyzed using a series of PSD-95 mutants (Fig. 7A). The expression of these constructs was compared with that of wild-type PSD-95 by immunoblotting with antibodies against the NH2-terminal region (amino acids 4-404) and against the central region (amino acids 353-504) of rat PSD-95. When 25 ng of cRNA was injected into an oocyte for each mutant, there was no significant difference in the expression of these constructs at the protein level (Fig. 7, B and C). The deletion mutant lacking the SH3 domain (Delta SH3), the COOH-terminal half-region including the SH3 and guanylate kinase-like domains (Delta C-half), or the PDZ1 domain (Delta PDZ1) had the same effect on the glutamate sensitivity of the channels as full-length PSD-95 (Fig. 8). Deletion of the PDZ2 domain (Delta PDZ2) significantly decreased the ratio of current responses between 100 and 10 µM L-glutamate from that of full-length PSD-95. A double PSD domain deletion mutant lacking both PDZ1 and PDZ2 domains (Delta PDZ(1+2)) and a triple PDZ domain deletion mutant (Delta PDZ(1+2+3)) further decreased the ratio to that observed in oocytes expressing the channels without PSD-95 (Fig. 8). Since two cysteine residues near the NH2 terminus at positions 3 and 5 in PSD-95 have been shown to be critical for the in vivo interaction with the K+ channel (34, 35), we examined the role of these two cysteine residues in the channel modulation by PSD-95 using the mutant in which both of these cysteine residues were substituted to serine (C(3,5)S). This construct partially decreased the ratio from that of wild-type PSD-95 (Fig. 8). Deletion of both PDZ1 and PDZ2 domains from this mutant (C(3,5)SDelta PDZ(1+2)) further decreased the ratio to the level without PSD-95 (Fig. 8). Thus, the PDZ2 domain is critical for the action of PSD-95 on the glutamate sensitivity of the channels, although the PDZ1 domain and the NH2-terminal two cysteine residues play an additional role in it.


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 7.   Expression of mutant PSD-95 in oocytes. A, schematic diagram of the wild-type and mutant constructs of PSD-95 used in this study. The domains of PSD-95 are indicated. S·S, substitution of cysteines 3 and 5 with serine. B and C, immunoblotting of wild-type and mutant PSD-95 expressed in oocytes. Wild-type or mutant PSD-95 cRNA (25 ng) was injected into an oocyte expressing the epsilon 2/zeta 1 NMDA receptor. Immunoblotting was performed as described under "Experimental Procedures" using polyclonal antibodies against the NH2-terminal region (amino acids 4-404) (B) and a monoclonal antibody against the central region (amino acids 353-504) (C) of rat PSD-95.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 8.   Effects of wild-type and mutant PSD-95 on the glutamate sensitivity of epsilon 2/zeta 1 NMDA receptor channels. Wild-type or mutant PSD-95 cRNA (25 ng) was injected into an oocyte expressing the epsilon 2/zeta 1 NMDA receptor. A ratio of current responses is presented between 100 and 10 µM L-glutamate in the presence of 10 µM glycine. The data shown are the mean ± S.E. of the number of oocytes indicated in parentheses. *, p < 0.05, and **, p < 0.01 compared with oocytes co-expressing the NMDA receptor with wild-type PSD-95.


    DISCUSSION

PSD-95 has been shown to induce clustering of the epsilon 2 (NR2B) NMDA receptor (23). In addition to this function of PSD-95, the present study demonstrated that it functionally modulates the channel activity of the epsilon 2/zeta 1 heteromeric NMDA receptor. PSD-95 decreased the sensitivity of the channels to L-glutamate (Fig. 3) and inhibited the protein kinase C-mediated potentiation of the channels (Figs. 4 and 5). Furthermore, we demonstrated that the interaction between the COOH terminus of the epsilon 2 subunit and the PDZ2 domain of PSD-95 plays a critical role in the decrease in glutamate sensitivity (Fig. 8). On the other hand, other basic channel properties of the epsilon 2/zeta 1 NMDA receptor such as a voltage-dependent Mg2+ block, a requirement for glycine as co-agonist, and inhibition of the channels by ifenprodil are not significantly altered by PSD-95. Our results indicate that PSD-95 has inhibitory effects on epsilon 2/zeta 1 NMDA receptor channels, in contrast to the inward rectifier K+ channel Kir4.1. The channel activity of the latter channel is enhanced by PSD-95 in co-expressed cells (27). For epsilon 2/zeta 1 NMDA receptor channels, PSD-95 not only makes signal transmission more efficient by clustering the channels at postsynaptic sites, but also protects neuronal cells from excitotoxicity by decreasing the glutamate sensitivity and by inhibiting the protein kinase C-mediated potentiation.

Our mutational studies indicate that a direct interaction between the COOH terminus of the NMDA receptor epsilon 2 subunit and the PDZ2 domain of PSD-95 is responsible for the decrease in the glutamate sensitivity of the channels because PSD-95 could not decrease the sensitivity of the mutant NMDA receptor lacking the COOH-terminal four amino acid residues (Fig. 6) and because the activity to decrease the sensitivity was significantly reduced in any mutants of PSD-95 lacking the PDZ2 domain (Fig. 8). It has been reported that the epsilon 2 subunit (NR2B) has a strong preference for the PDZ2 domain over the PDZ1 domain (19). In accord with this, deletion of the PDZ2 domain did not completely abolish the effect of PSD-95, whereas a double PSD domain deletion of both PDZ1 and PDZ2 domains did (Fig. 8). The interaction between the COOH terminus of the channels and the PDZ2 domain also induces channel clustering (23, 34). Does channel clustering decrease glutamate sensitivity? The NH2-terminal two cysteine residues of PSD-95 have been shown to be essential for clustering of Shaker-type K+ channel Kv1.4, but not for the binding of the COOH terminus of the channel to the PDZ1 or PDZ2 domain (34). If this is true of the NMDA receptor, our results suggest that the binding (but not the clustering) decreases glutamate sensitivity because the activity to decrease the glutamate sensitivity was still retained to some extent (Fig. 8) when cysteines 3 and 5 of PSD-95 were substituted with serine, which completely abolishes the channel clustering activity (34). This intermediate effect of the cysteine substitution might be explained by the finding that cysteines 3 and 5 are palmitoylated, which is essential for membrane targeting of PSD-95 (35). The PSD-95 mutant, which is not recruited to the plasma membrane, might not efficiently exert its action on the channels even though it has a PDZ2 domain.

The EC50 of NMDA receptor channels for L-glutamate in neurons has been measured in cultured neurons. The reported values vary from 2.3 to 16 µM (36, 37). Lower EC50 values (0.8-1.5 µM) were reported, including this study, in oocytes expressing epsilon 2/zeta 1 (or NR1/NR2B) NMDA receptor channels (28, 38). These values cannot simply be compared because a neuron may not express only one type of NMDA receptors. Furthermore, the kinetics of the channel in neurons are not simple since the desensitization occurs during measurement. Despite these uncertainties, the EC50 obtained from oocytes co-expressing the epsilon 2/zeta 1 NMDA receptor with PSD-95 (Fig. 3) is in good agreement with EC50 values obtained from neurons. We do not know the physiological significance of this effect of PSD-95 on the channels. PSD-95 may play a protective role in neuronal excitotoxicity, lowering the sensitivity of the NMDA receptor channels to glutamate.

In this study, we demonstrated that PSD-95 suppresses the protein kinase C-mediated potentiation of NMDA receptor channels (Figs. 4 and 5). It is unlikely that PSD-95 directly inhibits the kinase activity of protein kinase C in oocytes because PSD-95 had no effect on the desensitization of metabotropic glutamate receptor-5 in oocytes co-expressing both proteins, which was shown to require phosphorylation of metabotropic glutamate receptor-5 by protein kinase C (33). Further study is necessary to elucidate how the NMDA receptor channels are potentiated by protein kinase C and how this potentiation is modulated by PSD-95.

Although epsilon 2/zeta 1 NMDA channels in oocytes are potentiated by the treatments that activate protein kinase C (Fig. 4) (31, 32), it is still controversial whether phosphorylation by protein kinase C potentiates the NMDA receptor channels in vivo. The protein kinase C-mediated potentiation of the channels is observed in dorsal horn neurons in spinal cord and caudal brain stem (5, 39), whereas activation of the kinase does not potentiate NMDA receptor-mediated responses in CA1 hippocampal neurons (40) where the epsilon 2 subunit is highly expressed (9, 10, 28). The latter observation can be explained in part by our finding that PSD-95 suppresses the protein kinase C-mediated potentiation of epsilon 2/zeta 1 NMDA receptor channels.

The induction of LTP at synapses requires Ca2+ entry into the postsynaptic dendritic spine via NMDA receptors (15). LTP is triggered by delivering synchronous high frequency stimulation, a tetanus, to the pathway. In the widely accepted model, tetanic stimulation sufficiently depolarizes the postsynaptic membranes, which reduces the extent of the Mg2+-induced block of NMDA receptors and allows Ca2+ influx (15). Consistent with this model, the PSD-95-interacting NMDA receptors also showed a voltage-dependent Mg2+ block of the channels (data not shown). A number of evidences indicate that the activation of protein kinase C is necessary for induction of LTP (15, 41). If the activation of protein kinase C is induced by tetanic stimulation, PSD-95 may play a protective role regarding the NMDA receptor channels, preventing further potentiation of the channels and excess Ca2+ influx.

In this study, we demonstrated that PSD-95 functionally modulates the channel activity of the epsilon 2/zeta 1 heteromeric NMDA receptor. Recently, a number of proteins were reported to bind to PSD-95. GKAP (guanylate kinase-associated protein) or SAPAP (SAP90/PSD-95-associated protein) binds to the guanylate kinase-like domain (42-44). Neuroligin (45) and CRIPT (cysteine-rich interactor of PDZ three) (46) bind to the PDZ3 domain. It remains to be seen whether these PSD-95-binding proteins affect the channel modulation by PSD-95.

    ACKNOWLEDGEMENT

We thank Dr. Masayoshi Mishina (University of Tokyo) for the NMDA receptor cDNA clones.

    FOOTNOTES

* This work was supported in part by the Watanabe Memorial Foundation (to M. I.) and by a grant-in-aid for COE research from the Ministry of Education, Science, Sports, and Culture of Japan (to K. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed. Tel.: 81-836-22-2216; Fax: 81-836-22-2321; E-mail: minui{at}po.cc.yamaguchi-u.ac.jp.

    ABBREVIATIONS

The abbreviations used are: NMDA, N-methyl D-aspartate; LTP, long-term potentiation; PDZ, PSD-95/Dlg/Z0-1; TPA, 12-O-tetradecanoylphorbol-13-acetate.

    REFERENCES
Top
Abstract
Introduction
References
  1. Collingridge, G. L., and Lester, R. A. (1989) Pharmacol. Rev. 41, 143-210[Medline] [Order article via Infotrieve]
  2. Hollmann, M., and Heinemann, S. (1994) Annu. Rev. Neurosci. 17, 31-108[CrossRef][Medline] [Order article via Infotrieve]
  3. McBain, C. J., and Mayer, M. L. (1994) Physiol. Rev. 74, 723-760[Free Full Text]
  4. Sucher, N. J., Awobuluyi, M., Choi, Y. B., and Lipton, S. A. (1996) Trends Pharmacol. Sci. 17, 348-355[CrossRef][Medline] [Order article via Infotrieve]
  5. Chen, L., and Huang, L. Y. (1991) Neuron 7, 319-326[CrossRef][Medline] [Order article via Infotrieve]
  6. Yamazaki, M., Mori, H., Araki, K., Mori, K. J., and Mishina, M. (1992) FEBS Lett. 300, 39-45[CrossRef][Medline] [Order article via Infotrieve]
  7. Wang, Y. T., and Salter, M. W. (1994) Nature 369, 233-235[CrossRef][Medline] [Order article via Infotrieve]
  8. Chen, S., and Leonard, J. P. (1996) J. Neurochem. 67, 194-200[Medline] [Order article via Infotrieve]
  9. Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., and Seeburg, P. H. (1992) Science 256, 1217-1221[Medline] [Order article via Infotrieve]
  10. Nakanishi, S. (1992) Science 258, 597-603[Medline] [Order article via Infotrieve]
  11. Watanabe, M., Inoue, Y., Sakimura, K., and Mishina, M. (1992) Neuroreport 3, 1138-1140[Medline] [Order article via Infotrieve]
  12. Li, Y., Erzurumlu, R. S., Chen, C., Jhaveri, S., and Tonegawa, S. (1994) Cell 76, 427-437[Medline] [Order article via Infotrieve]
  13. Sakimura, K., Kutsuwada, T., Ito, I., Manabe, T., Takayama, C., Kushiya, E., Yagi, T., Aizawa, S., Inoue, Y., Sugiyama, H., and Mishina, M. (1995) Nature 373, 151-155[CrossRef][Medline] [Order article via Infotrieve]
  14. Kutsuwada, T., Sakimura, K., Manabe, T., Takayama, C., Katakura, N., Kushiya, E., Natsume, R., Watanabe, M., Inoue, Y., Yagi, T., Aizawa, S., Arakawa, M., Takahashi, T., Nakamura, Y., Mori, H., and Mishina, M. (1996) Neuron 16, 333-344[Medline] [Order article via Infotrieve]
  15. Bliss, T. V., and Collingridge, G. L. (1993) Nature 361, 31-39[CrossRef][Medline] [Order article via Infotrieve]
  16. Cho, K. O., Hunt, C. A., and Kennedy, M. B. (1992) Neuron 9, 929-942[Medline] [Order article via Infotrieve]
  17. Kistner, U., Wenzel, B. M., Veh, R. W., Cases-Langhoff, C., Garner, A. M., Appeltauer, U., Voss, B., Gundelfinger, E. D., and Garner, C. C. (1993) J. Biol. Chem. 268, 4580-4583[Abstract/Free Full Text]
  18. Kornau, H. C., Schenker, L. T., Kennedy, M. B., and Seeburg, P. H. (1995) Science 269, 1737-1740[Medline] [Order article via Infotrieve]
  19. Niethammer, M., Kim, E., and Sheng, M. (1996) J. Neurosci. 16, 2157-2163[Abstract]
  20. Lue, R. A., Marfatia, S. M., Branton, D., and Chishti, A. H. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9818-9822[Abstract/Free Full Text]
  21. Muller, B. M., Kistner, U., Veh, R. W., Cases-Langhoff, C., Becker, B., Gundelfinger, E. D., and Garner, C. C. (1995) J. Neurosci. 15, 2354-2366[Abstract]
  22. Brenman, J. E., Chao, D. S., Gee, S. H., McGee, A. W., Craven, S. E., Santillano, D. R., Wu, Z., Huang, F., Xia, H., Peters, M. F., Froehner, S. C., and Bredt, D. S. (1996) Cell 84, 757-767[Medline] [Order article via Infotrieve]
  23. Kim, E., Cho, K. O., Rothschild, A., and Sheng, M. (1996) Neuron 17, 103-113[Medline] [Order article via Infotrieve]
  24. Muller, B. M., Kistner, U., Kindler, S., Chung, W. J., Kuhlendahl, S., Fenster, S. D., Lau, L. F., Veh, R. W., Huganir, R. L., Gundelfinger, E. D., and Garner, C. C. (1996) Neuron 17, 255-265[Medline] [Order article via Infotrieve]
  25. Kim, E., Niethammer, M., Rothschild, A., Jan, Y. N., and Sheng, M. (1995) Nature 378, 85-88[CrossRef][Medline] [Order article via Infotrieve]
  26. Cohen, N. A., Brenman, J. E., Snyder, S. H., and Bredt, D. S. (1996) Neuron 17, 759-767[Medline] [Order article via Infotrieve]
  27. Horio, Y., Hibino, H., Inanobe, A., Yamada, M., Ishii, M., Tada, Y., Satoh, E., Hata, Y., Takai, Y., and Kurachi, Y. (1997) J. Biol. Chem. 272, 12885-12888[Abstract/Free Full Text]
  28. Kutsuwada, T., Kashiwabuchi, N., Mori, H., Sakimura, K., Kushiya, E., Araki, K., Meguro, H., Masaki, H., Kumanishi, T., Arakawa, M., and Mishina, M. (1992) Nature 358, 36-41[CrossRef][Medline] [Order article via Infotrieve]
  29. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
  30. Williams, K. (1993) Mol. Pharmacol. 44, 851-859[Abstract]
  31. Mori, H., Yamakura, T., Masaki, H., and Mishina, M. (1993) Neuroreport 4, 519-522[Medline] [Order article via Infotrieve]
  32. Wagner, D. A., and Leonard, J. P. (1996) Neuropharmacology 35, 29-36[CrossRef][Medline] [Order article via Infotrieve]
  33. Gereau, R. W., and Heinemann, S. F. (1998) Neuron 20, 143-151[Medline] [Order article via Infotrieve]
  34. Hsueh, Y. P., Kim, E., and Sheng, M. (1997) Neuron 18, 803-814[Medline] [Order article via Infotrieve]
  35. Topinka, J. R., and Bredt, D. S. (1998) Neuron 20, 125-134[Medline] [Order article via Infotrieve]
  36. Patneau, D. K., and Mayer, M. L. (1990) J. Neurosci. 10, 2385-2399[Abstract]
  37. Sather, W., Dieudonne, S., MacDonald, J. F., and Ascher, P. (1992) J. Physiol. (Lond.) 450, 643-672[Abstract]
  38. Laube, B., Hirai, H., Sturgess, M., Betz, H., and Kuhse, J. (1997) Neuron 18, 439-503[CrossRef][Medline] [Order article via Infotrieve]
  39. Gerber, G., Kangrga, I., Ryu, P. D., Larew, J. S., and Randic, M. (1989) J. Neurosci. 9, 3606-3617[Abstract]
  40. Markram, H., and Segal, M. (1992) J. Physiol. (Lond.) 457, 491-501[Abstract]
  41. Larkman, A. U., and Jack, J. J. (1995) Curr. Opin. Neurobiol. 5, 324-334[CrossRef][Medline] [Order article via Infotrieve]
  42. Takeuchi, M., Hata, Y., Hirao, K., Toyoda, A., Irie, M., and Takai, Y. (1997) J. Biol. Chem. 272, 11943-11951[Abstract/Free Full Text]
  43. Kim, E., Naisbitt, S., Hsueh, Y. P., Rao, A., Rothschild, A., Craig, A. M., and Sheng, M. (1997) J. Cell Biol. 136, 669-678[Abstract/Free Full Text]
  44. Kawashima, N., Takamiya, K., Sun, J., Kitabatake, A., and Sobue, K. (1997) FEBS Lett. 418, 301-304[CrossRef][Medline] [Order article via Infotrieve]
  45. Irie, M., Hata, Y., Takeuchi, M., Ichtchenko, K., Toyoda, A., Hirao, K., Takai, Y., Rosahl, T. W., and Sudhof, T. C. (1997) Science 277, 1511-1515[Abstract/Free Full Text]
  46. Niethammer, M., Valtschanoff, J. G., Kapoor, T. M., Allison, D. W., Weinberg, T. M., Craig, A. M., and Sheng, M. (1998) Neuron 20, 693-707[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.